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Abstract
There has long been interest in determining if mass ivermectin administration for onchocerciasis
has 'unknowingly' interrupted lymphatic filariasis (LF) transmission where the endemicity of the two
diseases' overlaps. We studied 11 communities in central Nigeria entomologically for LF by
performing mosquito dissections on Anopheline LF vectors. Six of the communities studied were
located within an onchocerciasis treatment zone, and five were located outside of that zone.
Communities inside the treatment zone had been offered ivermectin treatment for two-five years,
with a mean coverage of 81% of the eligible population (range 58–95%). We found 4.9% of
mosquitoes were infected with any larval stage of W. bancrofti in the head or thorax in 362
dissections in the untreated villages compared to 4.7% infected in 549 dissections in the ivermectin
treated villages (Mantel-Haenszel ChiSquare 0.02, P = 0.9). We concluded that ivermectin annual
therapy for onchocerciasis has not interrupted transmission of Wuchereria bancrofti (the causative
agent of LF in Nigeria).
Findings
Ivermectin is an effective microfilaricidal oral medication
that is being distributed in mass drug administration pro-
grammes for two filarial diseases, onchocerciasis [1] and
lymphatic filariasis (LF) [2,3]. Both onchocerciasis and LF
are vector borne, with onchocerciasis transmitted by
Simulium black flies, and LF by Anopheline mosquitoes in
rural Africa. Merck and Co. donates ivermectin (Mecti-
zan®) to global control programmes for both these para-
sitic diseases, although annual ivermectin in combination
with albendazole (donated by GlaxoSmithKline) is rec-
ommended by WHO for the treatment of LF in Africa,
because of the presumed synergy [4,5], although this
remains in debate [6].
Of the two initiatives, the oldest is that for onchocerciasis
and ivermectin has been distributed in annual ivermectin
monotherapy (150 micrograms/kg) programmes in Africa
for over 16 years [1]. There has long been interest in deter-
mining if such ivermectin distribution for onchocerciasis
has 'unknowingly' interrupted LF transmission where the
endemicity of the two diseases' overlaps [7]. We had
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occasion to address this question in central Nigeria in
1999 while conducting Anopheline  entomological sam-
pling for LF in and outside of onchocerciasis programme
zones.
The study was performed in Plateau and Nasarawa States,
Nigeria, as part of an integrated onchocerciasis, schisto-
somiasis, and lymphatic filariaisis programme described
by Hopkins et al. [8]. Twelve of the 30 local government
areas (LGA) in these two states are onchocerciasis treat-
ment zones and have been offered annual ivermectin
monotherapy since 1993. LF mapping in 1998 designated
all 30 LGA for combined ivermectin and albendazole
mass treatment for LF. Prior to launching the larger LF
treatment programme, we sought (in 1999) entomology
sentinel sites for a longitudinal study of treatment impact
on LF transmission [9]. To identify villages with high
baseline infection rates, our team captured and dissected
resting Anopheles gambiae sl and An. funestus in randomly
selected households in 11 villages, 5 of which were out-
side of the onchocerciasis ivermectin treatment zone, and
6 were inside the treatment zone. Treatment coverage for
those six ivermectin treatment villages during the years
1995–1999 ranged from 58–95% of the eligible popula-
tion (Table 1) with a mean of 81%.
After obtaining permission from local village chiefs and
residents of the selected household, trained collectors
used aspirators and torches to capture indoor resting
Anopheline mosquitoes; 75% of these were Anopheles
gambiae sl, the remainder were An.funestus. The mosqui-
toes, most of which were blood fed, were immediately
transferred to screened paper cups and kept alive in an ice
chest containing wet towels until dissected later that same
day. At that time the mosquitoes were killed, placed on a
glass slide, separated into head, abdomen and thorax,
teased apart in normal saline, and examined under a bin-
ocular microscope. Infection rates were based on the find-
ing of any larval stage of W. bancrofti in head or thorax.
Microfilaria in the abdomen where not considered in the
infection rate calculations.
LF antigenemia testing occurred on a separate occasion
using the rapid ICT card test [10] (AMRAD Corporation
Ltd., North South Wales, Australia). The test was per-
formed as described by Eigege [11] on finger stick blood
samples of 30 randomly selected adult male residents
from five of the six treated villages and in 50 individuals
in one of the six untreated villages (Gwamlar).
We found that the untreated village of Gwamlar, had both
the highest mosquito infection rate (20%) and the highest
antigenemia rate (58%). However, no statistically signifi-
cant entomological differences could be demonstrated
between the villages in treated and untreated zones (Fig-
ure 1): 4.9% of mosquitoes were infected in 362 dissec-
tions in the untreated villages compared to 4.7% infected
in 549 dissections in the ivermectin treated villages (Man-
tel-Haenszel ChiSquare 0.02, P = 0.9).
In contrast LF antigenemia (Table 1) was less common
among the 150 adult residents examined in the ivermectin
treated villages (mean 41%, village range 27–47%) com-
pared to the untreated village of Gwamlar, having the
forementioned 58% antigenemia prevalence (ChiSquare
4.5, P = 0.03).
We conclude therefore, that ivermectin monotherapy for
onchocerciasis has not been sufficient to interrupt trans-
mission of LF in central Nigeria. Among treated villages,
mosquito infection rates in treated and untreated areas
were statistically equivalent, and antigenemia rates in
treated villages were unacceptably high (although lower
than those in Gwamlar). Mosquito infection rates were
indeed highest in the two villages (Lankan and Mungko-
hot) with the longest treatment history (5 years) with ade-
quate coverage. Our conclusion is in support of the
findings of Kyelem et al., [7] who, working in Burkina
Faso, demonstrated that ivermectin monotherapy given
twice per year for onchocerciasis reduced but did not
interrupt LF transmission there.
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Table: Ivermectin treatment coverage of the eligible population (1995–1999) and LF antigenemia (1999) among male residents in five 
ivermectin treated villages, with 1999 LF antigenemia in one untreated village (Gwamlar)
Village Angwan Lemu Apanda Bakin-Kogi Lankan Mungkohot Gwamlar
Ivermectin rounds 2 2255 -
Mean coverage (range) 91.4% (91–92) 66.9% (58–76) 85.3% (82–89) 85.9% (65–95) 77% (73–80) -
1999 coverage 92% 58% 89% 90% 80% -
% LF antigenemia in males (n) 40% (30) 43% (30) 27% (30) 47% (30) 47% (30) 58% (50)Publish with BioMed Central    and   every 
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